Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Endorses Takeda’s HAE Med and More, Drops AZ’s Asthma Drug
March 4, 2022
- MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts
March 4, 2022
- Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
- Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
March 4, 2022
- Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
- Japan Ponders Fourth COVID-19 Vaccine Shot after Autumn
March 3, 2022
- Pfizer’s Paxlovid Listed in MHLW’s COVID-19 Guide
March 3, 2022
- Yervoy Infusion Time Changed for Melanoma: Label Update
March 2, 2022
- Japan Cabinet OKs Draft Bill to Amend PMD Law
March 2, 2022
- Pfizer’s Paxlovid Can Now Be Used Across Japan on In-Hospital Dispensing
March 1, 2022
- Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
March 1, 2022
- Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
- 7 Drugs to Be Eligible for Health Coverage for Fertility Treatment
March 1, 2022
- Bayer’s Finerenone, Samsca Prodrug, Chugai Bispecific and More Clear PAFSC Review
February 28, 2022
- MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022
- MHLW OKs 48 More Health Damage Claims for COVID-19 Vaccines
February 28, 2022
- Orphan Tag Given to Soticlestat, Marstacimab, Imfinzi
February 28, 2022
- MHLW Plans FY2022 Discussion over Linking National Health Database with Mortality Data
February 28, 2022
- Japan Pledges US$300 Million Contribution for CEPI
February 28, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…